These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33740629)

  • 1. Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic ductal adenocarcinoma.
    Shimomura O; Oda T; Hashimoto S; Doi M; Hiroshima Y; Numajiri H; Takahashi K; Furuya K; Miyazaki Y; Owada Y; Ogawa K; Ohara Y; Hisakura K; Akashi Y; Enomoto T; Sakurai H
    Surg Oncol; 2021 Jun; 37():101542. PubMed ID: 33740629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial).
    Shimomura O; Endo M; Makishima H; Yamada T; Hashimoto S; Numajiri H; Miyazaki Y; Doi M; Furuya K; Takahashi K; Moriwaki T; Hasegawa N; Yamamoto Y; Niisato Y; Kobayashi M; Mizumoto M; Nakai K; Saito T; Hoshiai S; Saida T; Mathis BJ; Mori K; Nakajima T; Tsuchiya K; Sakurai H; Oda T
    BMC Cancer; 2023 Jul; 23(1):624. PubMed ID: 37403011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study.
    Takano N; Yamada S; Hirakawa A; Yokoyama Y; Kawashima H; Maeda O; Okada T; Ohno E; Yamaguchi J; Ishikawa T; Sonohara F; Suenaga M; Takami H; Hayashi M; Niwa Y; Hirooka Y; Ito Y; Naganawa S; Ando Y; Nagino M; Goto H; Fujii T; Kodera Y
    Nagoya J Med Sci; 2019 May; 81(2):233-239. PubMed ID: 31239592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma.
    McIntyre CA; Cohen NA; Goldman DA; Gonen M; Sadot E; O'Reilly EM; Varghese AM; Yu KH; Balachandran VP; Soares KC; D'Angelica MI; Drebin JA; Kingham TP; Allen PJ; Wei AC; Jarnagin WR
    J Surg Oncol; 2022 Mar; 125(3):425-436. PubMed ID: 34719035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression.
    Kobayashi M; Mizuno S; Murata Y; Kishiwada M; Usui M; Sakurai H; Tabata M; Ii N; Yamakado K; Inoue H; Shiraishi T; Yamada T; Isaji S
    Pancreas; 2014 Apr; 43(3):350-60. PubMed ID: 24622063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis.
    Mataki Y; Kurahara H; Idichi T; Tanoue K; Hozaka Y; Kawasaki Y; Iino S; Maemura K; Shinchi H; Ohtsuka T
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer.
    Takano N; Yamada S; Sonohara F; Inokawa Y; Takami H; Hayashi M; Koike M; Fujii T; Kodera Y
    Surg Today; 2021 Jul; 51(7):1099-1107. PubMed ID: 33483785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma.
    Yanagimoto H; Satoi S; Yamamoto T; Yamaki S; Hirooka S; Kotsuka M; Ryota H; Ishida M; Matsui Y; Sekimoto M
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
    Konstantinidis IT; Warshaw AL; Allen JN; Blaszkowsky LS; Castillo CF; Deshpande V; Hong TS; Kwak EL; Lauwers GY; Ryan DP; Wargo JA; Lillemoe KD; Ferrone CR
    Ann Surg; 2013 Apr; 257(4):731-6. PubMed ID: 22968073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
    Cecchini M; Miccio JA; Pahade J; Lacy J; Salem RR; Johnson SB; Blakaj A; Stein S; Kortmansky JS; Johung KL
    Pancreas; 2020 Aug; 49(7):904-911. PubMed ID: 32658074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma.
    Hayasaki A; Murata Y; Usui M; Hibi T; Ito T; Iizawa Y; Kato H; Tanemura A; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Sakurai H; Yoshida T; Isaji S
    Pancreas; 2018 Apr; 47(4):390-399. PubMed ID: 29517632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report.
    Okura R; Takano S; Yokota T; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Miyazaki M; Ohtsuka M
    Mol Clin Oncol; 2018 Oct; 9(4):389-393. PubMed ID: 30214727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer.
    Okano K; Suto H; Oshima M; Ando Y; Nagao M; Kamada H; Kobara H; Masaki T; Okuyama H; Okita Y; Tsuji A; Suzuki Y
    Jpn J Clin Oncol; 2018 May; 48(5):434-441. PubMed ID: 29590448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion surgery for initially unresectable locally advanced pancreatic ductal adenocarcinoma after chemotherapy followed by carbon-ion radiotherapy: a case report.
    Watanabe Y; Tatsuguchi T; Date K; Shinkawa T; Kuga H; Tamiya S; Nishihara K; Nakano T
    J Med Case Rep; 2024 Jan; 18(1):13. PubMed ID: 38200536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
    Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
    Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis.
    Lindemann J; du Toit L; Kotze U; Bernon M; Krige J; Jonas E
    HPB (Oxford); 2021 Feb; 23(2):173-186. PubMed ID: 33268268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement.
    Jolissaint JS; Reyngold M; Bassmann J; Seier KP; Gönen M; Varghese AM; Yu KH; Park W; O'Reilly EM; Balachandran VP; D'Angelica MI; Drebin JA; Kingham TP; Soares KC; Jarnagin WR; Crane CH; Wei AC
    Ann Surg; 2021 Dec; 274(6):894-901. PubMed ID: 34269717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.